Download PDF
Neuropediatrics 2013; 44(06): 314-323
DOI: 10.1055/s-0033-1358600
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Pediatric Idiopathic Inflammatory Myopathies: An Update on Diagnostic and Treatment Strategies

Wolfgang Muller-Felber
1   Dr. von Hauner Children's Hospital, Ludwig-Maximilian University of Munich, Munich, Germany
,
Julia Wanschitz
2   Neurological Department, Innsbruck Medical University, Innsbruck, Austria
,
Katharina Vill
1   Dr. von Hauner Children's Hospital, Ludwig-Maximilian University of Munich, Munich, Germany
,
Matthias Baumann
3   Department of Paediatrics I, Paediatric Neurology, Innsbruck Medical University, Innsbruck, Austria
› Author Affiliations
Further Information

Publication History

02 July 2013

21 August 2013

Publication Date:
07 November 2013 (online)

    Permissions and Reprints

Abstract

Diagnostic approach and treatment of idiopathic inflammatory myopathies have changed considerably during the past decades. In this review, new insights in the pathogenesis, the role of muscle biopsy, and magnetic resonance imaging in the diagnostic process in children with suspected myositis are discussed. Current treatment strategies and complication management is described in detail.

Keywords

inflammatory myopathies - juvenile dermatomyositis - children - muscle biopsy
 

  • References

  • 1 Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371 (9631) 2201-2212
    CrossrefPubMedGoogle Scholar
  • 2 Martin N, Krol P, Smith S , et al; Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) 2011; 50 (1) 137-145
    CrossrefPubMedGoogle Scholar
  • 3 Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011; 7 (11) 664-675
    CrossrefPubMedGoogle Scholar
  • 4 Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314 (6) 329-334
    CrossrefPubMedGoogle Scholar
  • 5 Ostrowski RA, Sullivan CL, Seshadri R, Morgan GA, Pachman LM. Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. Arthritis Rheum 2010; 62 (5) 1533-1538
    CrossrefPubMedGoogle Scholar
  • 6 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8) 403-407
    CrossrefPubMedGoogle Scholar
  • 7 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (7) 344-347
    CrossrefPubMedGoogle Scholar
  • 8 Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34 (8) 732-736
    CrossrefPubMedGoogle Scholar
  • 9 Mendez EP, Lipton R, Ramsey-Goldman R , et al; NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49 (3) 300-305
    CrossrefPubMedGoogle Scholar
  • 10 Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol 2010; 32 (3) 189-191
    CrossrefPubMedGoogle Scholar
  • 11 Sato JO, Sallum AM, Ferriani VP , et al; Rheumatology Committee of the São Paulo Paediatrics Society. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009; 27 (6) 1031-1038
    PubMedGoogle Scholar
  • 12 McCann LJ, Juggins AD, Maillard SM , et al; Juvenile Dermatomyositis Research Group. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45 (10) 1255-1260
    CrossrefPubMedGoogle Scholar
  • 13 Rider LG. The heterogeneity of juvenile myositis. Autoimmun Rev 2007; 6 (4) 241-247
    CrossrefPubMedGoogle Scholar
  • 14 Shah M, Mamyrova G, Targoff IN , et al; Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92 (1) 25-41
    CrossrefPubMedGoogle Scholar
  • 15 Wedderburn LR, Varsani H, Li CK , et al; UK Juvenile Dermatomyositis Research Group. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007; 57 (7) 1192-1201
    CrossrefPubMedGoogle Scholar
  • 16 López de Padilla CM, Vallejo AN, McNallan KT , et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007; 56 (5) 1658-1668
    CrossrefPubMedGoogle Scholar
  • 17 Rostasy KM, Schmidt J, Bahn E , et al. Distinct inflammatory properties of late-activated macrophages in inflammatory myopathies. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/ed the Gaetano Conte Academy for the study of striated muscle diseases 2008. 27. 49-53
  • 18 Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve 2010; 41 (5) 581-592
    CrossrefPubMedGoogle Scholar
  • 19 Coley W, Rayavarapu S, Nagaraju K. Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies. Arthritis Res Ther 2012; 14 (2) 209
    CrossrefPubMedGoogle Scholar
  • 20 Vegosen LJ, Weinberg CR, O'Hanlon TP, Targoff IN, Miller FW, Rider LG. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum 2007; 56 (8) 2719-2728
    CrossrefPubMedGoogle Scholar
  • 21 Pachman LM, Lipton R, Ramsey-Goldman R , et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53 (2) 166-172
    CrossrefPubMedGoogle Scholar
  • 22 Manlhiot C, Liang L, Tran D, Bitnun A, Tyrrell PN, Feldman BM. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford) 2008; 47 (4) 526-529
    PubMedGoogle Scholar
  • 23 Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 1986; 29 (11) 1365-1370
    CrossrefPubMedGoogle Scholar
  • 24 Massa M, Costouros N, Mazzoli F , et al. Self-epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum 2002; 46 (11) 3015-3025
    CrossrefPubMedGoogle Scholar
  • 25 Reed AM, Stirling JD. Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol 1995; 44 (3) 131-135
    PubMedGoogle Scholar
  • 26 Mamyrova G, O'Hanlon TP, Monroe JB , et al; Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54 (12) 3979-3987
    CrossrefPubMedGoogle Scholar
  • 27 Sanner H, Kirkhus E, Merckoll E , et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study. Arthritis Care Res (Hoboken) 2010; 62 (8) 1103-1111
    CrossrefPubMedGoogle Scholar
  • 28 Mamyrova G, O'Hanlon TP, Sillers L , et al; Childhood Myositis Heterogeneity Collaborative Study Group. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008; 58 (12) 3941-3950
    CrossrefPubMedGoogle Scholar
  • 29 Pachman LM, Liotta-Davis MR, Hong DK , et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43 (10) 2368-2377
    CrossrefPubMedGoogle Scholar
  • 30 Chinoy H, Platt H, Lamb JA , et al; UK Adult Onset Myositis Immunogenetic Collaboration and the Juvenile Dermatomyositis Research Group. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum 2008; 58 (10) 3247-3254
    CrossrefPubMedGoogle Scholar
  • 31 Reed AM, Picornell YJ, Harwood A, Kredich DW. Chimerism in children with juvenile dermatomyositis. Lancet 2000; 356 (9248) 2156-2157
    CrossrefPubMedGoogle Scholar
  • 32 Artlett CM, Ramos R, Jiminez SA, Patterson K, Miller FW, Rider LG ; Childhood Myositis Heterogeneity Collaborative Group. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Lancet 2000; 356 (9248) 2155-2156
    CrossrefPubMedGoogle Scholar
  • 33 Ye Y, van Zyl B, Varsani H, Wedderburn LR, Ramanan A, Gillespie KM ; Juvenile Dermatomyositis Research Group. Maternal microchimerism in muscle biopsies from children with juvenile dermatomyositis. Rheumatology (Oxford) 2012; 51 (6) 987-991
    CrossrefPubMedGoogle Scholar
  • 34 Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther 2013; 15 (2) 211
    CrossrefPubMedGoogle Scholar
  • 35 Gunawardena H, Wedderburn LR, Chinoy H , et al; Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60 (6) 1807-1814
    CrossrefPubMedGoogle Scholar
  • 36 Gunawardena H, Wedderburn LR, North J , et al; Juvenile Dermatomyositis Research Group UK. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47 (3) 324-328
    PubMedGoogle Scholar
  • 37 López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009; 60 (4) 1160-1172
    CrossrefPubMedGoogle Scholar
  • 38 Kim E, Cook-Mills J, Morgan G, Sredni ST, Pachman LM. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum 2012; 64 (11) 3809-3817
    CrossrefPubMedGoogle Scholar
  • 39 Sallum AM, Marie SK, Wakamatsu A , et al. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 2004; 31 (4) 801-807
    PubMedGoogle Scholar
  • 40 Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009; 60 (6) 1815-1824
    CrossrefPubMedGoogle Scholar
  • 41 Brunn A, Zornbach K, Hans VH, Haupt WF, Deckert M. Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 2012; 71 (10) 855-867
    CrossrefPubMedGoogle Scholar
  • 42 Tournadre A, Lenief V, Miossec P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 2010; 62 (7) 2144-2151
    PubMedGoogle Scholar
  • 43 Cappelletti C, Baggi F, Zolezzi F , et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011; 76 (24) 2079-2088
    CrossrefPubMedGoogle Scholar
  • 44 Bilgic H, Ytterberg SR, Amin S , et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60 (11) 3436-3446
    CrossrefPubMedGoogle Scholar
  • 45 Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011; 13 (6) 249
    CrossrefPubMedGoogle Scholar
  • 46 Reed AM, Peterson E, Bilgic H , et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012; 64 (12) 4078-4086
    CrossrefPubMedGoogle Scholar
  • 47 Nagaraju K, Casciola-Rosen L, Lundberg I , et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52 (6) 1824-1835
    CrossrefPubMedGoogle Scholar
  • 48 Li CK, Knopp P, Moncrieffe H , et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009; 175 (3) 1030-1040
    CrossrefPubMedGoogle Scholar
  • 49 Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008; 58 (11) 3585-3592
    CrossrefPubMedGoogle Scholar
  • 50 Rider LG, Lachenbruch PA, Monroe JB , et al; IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009; 60 (11) 3425-3435
    CrossrefPubMedGoogle Scholar
  • 51 Grouteau E, Chaix Y, Armbruster V , et al. [Acute orbital myositis and idiopathic inflammatory pseudotumor in children: three cases]. Arch Pediatr 1998; 5 (2) 153-158
    CrossrefPubMedGoogle Scholar
  • 52 Bakan S, Bakan AA, Cingu AK , et al. Myositic type of idiopathic orbital pseudotumor in a 4-year-old child: a case report. Case Rep Med 2012; 2012: 473856
    PubMedGoogle Scholar
  • 53 Sallum AM, Pivato FC, Doria-Filho U , et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008; 84 (1) 68-74
    PubMedGoogle Scholar
  • 54 Clemente G, Piotto DG, Barbosa C , et al. High frequency of calcinosis in juvenile dermatomyositis: a risk factor study. Rev Bras Reumatol 2012; 52 (4) 549-553
    CrossrefPubMedGoogle Scholar
  • 55 Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103 (6) 882-888
    PubMedGoogle Scholar
  • 56 Ramanan AV, Campbell-Webster N, Ota S , et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52 (11) 3570-3578
    CrossrefPubMedGoogle Scholar
  • 57 Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002; 28 (4) 833-857
    CrossrefPubMedGoogle Scholar
  • 58 Hesla RB, Karlson LK, McCauley RG. Milk of calcium fluid collection in dermatomyositis: ultrasound findings. Pediatr Radiol 1990; 20 (5) 344-346
    CrossrefPubMedGoogle Scholar
  • 59 Samson C, Soulen RL, Gursel E. Milk of calcium fluid collections in juvenile dermatomyositis: MR characteristics. Pediatr Radiol 2000; 30 (1) 28-29
    CrossrefPubMedGoogle Scholar
  • 60 Prestridge A, Morgan G, Ferguson L, Huang CC, Pachman LM. Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters in children. Arthritis Care Res (Hoboken) 2013; 65 (9) 1424-1431
    CrossrefPubMedGoogle Scholar
  • 61 Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012; 8: CD003643
    PubMedGoogle Scholar
  • 62 Morinishi Y, Oh-Ishi T, Kabuki T, Joh K. Juvenile dermatomyositis: clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol 2007; 17 (5) 413-417
    CrossrefPubMedGoogle Scholar
  • 63 Pouessel G, Deschildre A, Le Bourgeois M , et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol 2013; 48 (10) 1016-1025
    CrossrefPubMedGoogle Scholar
  • 64 Kobayashi I, Yamada M, Takahashi Y , et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003; 42 (2) 371-374
    PubMedGoogle Scholar
  • 65 Stefanski JC, Shetty AK. Abdominal pain in a girl with juvenile dermatomyositis. Clin Pediatr (Phila) 1998; 37 (9) 561-563
    CrossrefPubMedGoogle Scholar
  • 66 Braunstein EM, White SJ. Pneumatosis intestinalis in dermatomyositis. Br J Radiol 1980; 53 (634) 1011-1012
    CrossrefPubMedGoogle Scholar
  • 67 Ramanan AV, Sawhney S, Murray KJ. Central nervous system complications in two cases of juvenile onset dermatomyositis. Rheumatology (Oxford) 2001; 40 (11) 1293-1298
    CrossrefPubMedGoogle Scholar
  • 68 Rider LG, Miller FW, Targoff IN , et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37 (10) 1534-1538
    CrossrefPubMedGoogle Scholar
  • 69 Wedderburn LR, McHugh NJ, Chinoy H , et al; Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46 (12) 1786-1791
    CrossrefPubMedGoogle Scholar
  • 70 Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996; 23 (10) 1794-1797
    PubMedGoogle Scholar
  • 71 Targoff IN, Mamyrova G, Trieu EP , et al; Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54 (11) 3682-3689
    CrossrefPubMedGoogle Scholar
  • 72 Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36 (11) 2547-2551
    CrossrefPubMedGoogle Scholar
  • 73 Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008; 35 (5) 927-929
    PubMedGoogle Scholar
  • 74 Malattia C, Damasio MB, Madeo A , et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis 2013; (e-pub ahead of print). doi: 10.1136/annrheumdis-2012-202915
    PubMedGoogle Scholar
  • 75 May DA, Disler DG, Jones EA, Balkissoon AA, Manaster BJ. Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics 2000; 20 ( Spec No): S295-S315
    PubMedGoogle Scholar
  • 76 Ladd PE, Emery KH, Salisbury SR, Laor T, Lovell DJ, Bove KE. Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR Am J Roentgenol 2011; 197 (1) W153-W158
    CrossrefPubMedGoogle Scholar
  • 77 Huppertz HI, Kaiser WA. Serial magnetic resonance imaging in juvenile dermatomyositis—delayed normalization. Rheumatol Int 1994; 14 (3) 127-129
    CrossrefPubMedGoogle Scholar
  • 78 Banker BQ, Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 1966; 45 (4) 261-289
    CrossrefPubMedGoogle Scholar
  • 79 Danielsson O, Lindvall B, Gati I, Ernerudh J. Classification and diagnostic investigation in inflammatory myopathies: a study of 99 patients. J Rheumatol 2013; 40 (7) 1173-1182
    CrossrefPubMedGoogle Scholar
  • 80 Rider LG, Werth VP, Huber AM , et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11) S118-S157
    CrossrefPubMedGoogle Scholar
  • 81 Ruperto N, Ravelli A, Murray KJ , et al; Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42 (12) 1452-1459
    CrossrefPubMedGoogle Scholar
  • 82 Huber AM, Robinson AB, Reed AM , et al; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 2012; 64 (4) 546-553
    CrossrefPubMedGoogle Scholar
  • 83 Stringer E, Bohnsack J, Bowyer SL , et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 2010; 37 (9) 1953-1961
    CrossrefPubMedGoogle Scholar
  • 84 Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47 (4) 505-511
    CrossrefPubMedGoogle Scholar
  • 85 Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008; 59 (7) 989-995
    CrossrefPubMedGoogle Scholar
  • 86 Dalakas MC, Illa I, Dambrosia JM , et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329 (27) 1993-2000
    CrossrefPubMedGoogle Scholar
  • 87 Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 2011; 70 (12) 2089-2094
    CrossrefPubMedGoogle Scholar
  • 88 Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004; 43 (4) 491-496
    CrossrefPubMedGoogle Scholar
  • 89 Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr 2004; 163 (9) 561-562
    PubMedGoogle Scholar
  • 90 Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med 2005; 44 (11) 1197-1199
    CrossrefPubMedGoogle Scholar
  • 91 Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008; 27 (11) 1469-1471
    CrossrefPubMedGoogle Scholar
  • 92 Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56 (9) 3107-3111
    CrossrefPubMedGoogle Scholar
  • 93 Oddis CV, Reed AM, Aggarwal R , et al; RIM Study group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum 2013; 65 (2) 314-324
    CrossrefPubMedGoogle Scholar
  • 94 Dastmalchi M, Grundtman C, Alexanderson H , et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67 (12) 1670-1677
    CrossrefPubMedGoogle Scholar
  • 95 Hengstman GJ, De Bleecker JL, Feist E , et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59 (3-4) 159-163
    CrossrefPubMedGoogle Scholar
  • 96 Nassim JR, Connolly CK. Treatment of calcinosis universalis with aluminium hydroxide. Arch Dis Child 1970; 45 (239) 118-121
    CrossrefPubMedGoogle Scholar
  • 97 Eddy MC, Leelawattana R, McAlister WH, Whyte MP. Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J Clin Endocrinol Metab 1997; 82 (11) 3536-3542
    CrossrefPubMedGoogle Scholar
  • 98 Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001; 144 (4) 894-897
    CrossrefPubMedGoogle Scholar
  • 99 Bertorini TE, Sebes JI, Palmieri GM, Igarashi M, Horner LH. Diltiazem in the treatment of calcinosis in juvenile dermatomyositis. J Clin Neuromuscul Dis 2001; 2 (4) 191-193
    CrossrefPubMedGoogle Scholar
  • 100 Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001; 138 (5) 763-766
    PubMedGoogle Scholar
  • 101 Omori CH, Silva CA, Sallum AM , et al. Exercise training in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2012; 64 (8) 1186-1194
    PubMedGoogle Scholar
  • 102 Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?. Curr Rheumatol Rep 2005; 7 (6) 441-446
    CrossrefPubMedGoogle Scholar
  • 103 Ravelli A, Trail L, Ferrari C , et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62 (1) 63-72
    CrossrefPubMedGoogle Scholar